Phase 2 Lung Cancer Trial, Recruiting NCT06542159 Sponsor: Sun Yat-sen University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06542159
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with early-stage non-small cell lung cancer (confirmed by tissue sample or a PET-CT scan) that has not yet been treated, and either cannot have surgery or have chosen not to, or people who have a small number of cancer spots that have spread to the lung (no more than 3 spots, each no larger than 5cm).
  • People aged 18 or older, of any gender.
  • People who are generally able to carry out daily activities, with only mild limitations at most (this is measured on a standard scale called the ECOG scale, scored 0–2).
  • People whose blood counts are within acceptable ranges, including red blood cells, platelets, and a type of white blood cell called neutrophils (confirm specific values with trial site).
  • People whose kidneys are functioning well enough, based on blood and/or urine tests (confirm specific values with trial site).
  • People whose liver function is within acceptable ranges, based on blood tests (confirm specific values with trial site).
  • People whose lungs can breathe in at least a minimum amount of air, measured by a breathing test called FEV1 (confirm specific value with trial site).
  • People whose general blood test results (referred to as CB6) fall within the normal range.
  • People who, along with their family, agree to participate and sign a consent form.

Who may not be able to join:

  • People whose tumour has grown into the airways (bronchial invasion).
  • People who have another illness or condition that makes radiation therapy unsafe, such as an active infection, a heart attack within the past 6 months, or certain ongoing heart conditions such as unstable chest pain, heart failure, or irregular heartbeat that is not controlled.
  • People who are pregnant, breastfeeding, or have not had a pregnancy test, or anyone who is pregnant.
  • People with substance misuse issues, long-term heavy alcohol use, or HIV/AIDS.
  • People who have uncontrolled seizures or who are unable to make decisions for themselves due to a psychiatric condition.
  • People who have a history of severe allergic reactions or known serious sensitivities.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hui Liu, Professor, Sun yat-sen universtiy cancer center

Phone: +862087343031

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
22 May 2024
Est. completion
21 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of grade 2 or higher respiratory toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov